Bayer Nears a Tipping Point as Supreme Court, Drug Trials, and Management Overhaul Converge

Bayer shares cling to 200-day moving average as Supreme Court glyphosate decision looms, EMA validates Asundexian, new Phase 2 heart trial begins, and management reshuffles.

Bayer’s stock is dancing on a knife edge. At €36.06, it clings to its 200-day moving average — a technical level that separates a 30% year-to-date gain from a potential slide into selling pressure. But the real drama lies elsewhere. The company is juggling a pivotal Supreme Court ruling, a freshly validated European drug application, a new Phase 2 heart study, and a sweeping management reshuffle. Each piece could tip the balance for an equity that has spent 2024 clawing its way back.

The Supreme Court Looms Largest

For all the operational advances in the pharmaceutical pipeline, the single biggest catalyst for Bayer’s share price remains the legal battle over glyphosate. The U.S. Supreme Court is set to rule on the “Durnell” case, which asks whether state law can override a safety clearance issued by the federal Environmental Protection Agency (EPA). A victory for Bayer would extinguish tens of thousands of outstanding Roundup lawsuits overnight, removing the most persistent drag on the stock.

Analysts currently see a 60% probability of a favorable outcome. CEO Bill Anderson has vowed to cut legal risk before the year is out — win or lose. Meanwhile, the opt-out window for the Roundup class settlement has closed, though concrete numbers on how many plaintiffs walked away are not expected for several weeks.

The financial toll is already severe: Bayer bled over €2 billion in the first quarter alone to settle glyphosate and PCB claims. Singapore’s sovereign wealth fund trimmed its stake to 2.90%, a sign of institutional caution.

Asundexian Gets a Green Light in Europe

On the pharmaceutical front, the European Medicines Agency (EMA) has validated Bayer’s marketing application for Asundexian, triggering a formal review. The drug, once written off after failing in patients with atrial fibrillation in 2023, has been repositioned for secondary stroke prevention. A Phase 3 study showed markedly better outcomes, particularly a lower risk of bleeding — a key advantage over existing anticoagulants.

Bayer is also pursuing approvals in the U.S. and China, where regulators have already granted accelerated review pathways. Strokes are the second leading cause of death in Europe, giving Asundexian blockbuster potential if approved.

A New Heart Drug Enters the Race

Separately, Bayer has initiated a Phase 2 trial for an experimental compound designed to treat atrial fibrillation in adults. The goal is to restore normal heart rhythm without the need for electrical shocks. The drug originated from a collaboration with MIT and Harvard University, though patient recruitment has only just begun, and robust data remain years away.

Management Gets a Makeover

Behind the scenes, Bayer is reshaping its leadership to speed up decision-making. Trevor Thrun takes over the crucial U.S. consumer health market, while Analia de la Fuente steps in as the new global data chief. In the pharmaceuticals division, Dr. Jost Reinhard will lead the radiology business starting in August, succeeding Nelson Ambrogio. The appointments underscore Bayer’s push to operate leaner.

Market Sentiment and the Technical Picture

Operationally, the company is on solid ground. First-quarter revenue beat analyst forecasts and earnings per share came in at €2.81. Berenberg Bank recently nudged its price target to €40.50 while keeping a “Hold” rating, citing improved pharma profitability.

Yet the stock’s technical position is fragile. At €36.06, it sits just above the 200-day moving average. A decisive break below that line would invite selling pressure. Holding it allows investors to ride the momentum from a near-30% advance this year.

Bayer’s next few months will be defined by a balancing act: clinical milestones and corporate restructuring offer a positive narrative, but the Supreme Court’s gavel — and the legal overhang — still holds the final say.